Combined Nutrient Intake and Muscle Protein Synthesis

Aging Clinical Trial

Official title:

Combined Nutrient Intake and Muscle Protein Synthesis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01239277
• Other study ID #: MEC 10-3-080
• Status: Completed
• Phase: N/A
• First received: November 10, 2010
• Last updated: September 13, 2011
• Start date: January 2011
• Est. completion date: July 2011

Study information

• Verified date: September 2011
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

Dietary intervention to prevent sarcopenia in elderly people. The objective of this study is to test whether combined nutrient intake plays an important role in stimulation of the muscle protein growth in elderly people; and whether it represent effective strategies to overcome the impaired muscle protein synthesis in elderly when compared with young subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: July 2011
• Est. primary completion date: July 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 70 Years to 85 Years

Eligibility

Inclusion Criteria:

• males

• 70-85 years or 18-30 years

• BMI < 30

Exclusion Criteria:

• Type II diabetes

• All co morbidities interacting with mobility and muscle metabolism of the lower limbs

• Use of anticoagulants

• Patients suffering from Phenylketonuria

• Participation in any regular exercise programme

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Aging

Intervention

Other:
• protein
20g protein
• protein and carbohydrate
20g protein and 20g carbohydrate
• protein and leucine
20g protein, 2.5g leucine

Locations

Country	Name	City	State
Netherlands	Universiteit Maastricht, Bewegingswetenschappen	Maastricht	Limburg

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Muscle protein synthesis	Muscle protein synthesis will be expressed as fractional synthetic rate (FSR) by dividing the increment in enrichment in the product, i.e. protein-bound C13phe, by the enrichment of the precursor (=plasma availability).	6 h postprandial period	No

External Links

•   Information about research performed by the Maastricht Muscle Metabolism group at MUMC